Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

机译：雷尼单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力障碍的成本效益：英国医疗保健观点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundRanibizumab and aflibercept are alternative anti-vascular endothelial growth factor agents approved for the treatment of visual impairment (VI) due to diabetic macular edema (DME).

机译：背景雷珠单抗和阿柏西普是被批准用于治疗因糖尿病性黄斑水肿（DME）引起的视力障碍（VI）的替代性抗血管内皮生长因子药物。

著录项

期刊名称 ClinicoEconomics and Outcomes Research: CEOR
作者
Stephane A Régnier; William Malcolm; Jennifer Haig; Weiguang Xue;
展开▼
作者单位

展开▼
年(卷),期 2015(7),-1
年度 2015
页码 235–247
总页数 13
原文格式 PDF
正文语种
中图分类
关键词
Markov model cost-utility health states macula retina;

机译：马尔可夫模型;成本-效用;健康状态;黄斑;视网膜;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective [J] . Stephane A Régnier, William Malcolm, Jennifer Haig, ClinicoEconomics and Outcomes Research . 2015,第2期

机译：雷尼单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力障碍的成本效益：英国医疗保健观点
2. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective [J] . Adedokun Lola, Burke Colin Advances in therapy. . 2016,第1期

机译：雷尼单抗与阿柏西普治疗分支视网膜静脉阻塞继发性黄斑水肿的成本-效果：英国医疗保健的观点
3. Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results [J] . Duff Steve, Holekamp Nancy, Rajput Yamina Investigative ophthalmology & visual science . 2017,第8期

机译：FDA批准的抗VEGF治疗，Ranibizumab和AfliBercept的成本效益，用于来自美国的糖尿病性黄斑水肿：分析2年议定书T比较效果结果
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Prediction of visual acuity loss and indications for laser treatment in patients with diabetic macular edema using the Heidelberg Retina Tomograph. [D] . O'Neal, Dennis A. 2007

机译：使用海德堡视网膜断层扫描仪预测糖尿病性黄斑水肿患者的视力下降和激光治疗的适应症。
6. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective [O] . Lola Adedokun, Colin Burke -1

机译：雷尼珠单抗与阿柏西普治疗分支视网膜静脉阻塞继发性黄斑水肿的成本-效果：英国医疗保健的观点
7. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective [O] . 2016

机译：雷尼珠单抗与阿柏西普治疗继发于视网膜分支静脉阻塞的黄斑水肿的成本效果：英国医疗保健的观点

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

摘要

著录项

相似文献

相关主题

期刊订阅